Overview Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis Status: Not yet recruiting Trial end date: 2023-09-01 Target enrollment: Participant gender: Summary The primary objective of the study was to evaluate the efficacy and safety of 611 in chinese adults with moderate to severe atopic dermatitis. Phase: Phase 2 Details Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.